ABSTRACT
OBJECTIVE: Long noncoding RNAs (lncRNAs) are crucial regulators of lung adenocarcinoma (LUAD) progression. Herein, we explored the role of miR-490-3p and the underlying molecular mechanism involving key lncRNAs and pathways in LUAD. METHODS: Reverse transcription-quantitative PCR (RT-qPCR) was performed to detect the expression of lncRNA NEAT1 and miR-490-3p in LUAD cells and tissues. Western blotting was used to determine protein expression levels of the Ras homologous gene family member A/Rho-related protein kinase (RhoA/ROCK) signal pathway marker. Considering cell functions, Cell Counting Kit-8 (CCK-8), Transwell, and xenograft experiments were employed to evaluate LUAD cell proliferation, migration, and tumor growth, respectively. The relationship between miR-490-3p and lncRNA NEAT1 was analyzed using a luciferase reporter assay. RESULTS: Herein, we found that miR-490-3p expression was significantly low in LUAD cells and tissues. MiR-490-3p overexpression markedly suppressed tumor growth, the RhoA/ROCK signaling pathway, migration, and proliferation of LUAD cells. Moreover, lncRNA NEAT1, which is highly expressed in LUAD, was detected upstream of miR-490-3p. Upregulation of lncRNA NEAT1 exacerbated the behavior of LUAD cells and offset the suppressive influence of miR-490-3p-mediated upregulation on malignant LUAD cell behavior. CONCLUSION: MiR-490-3p sponging by lncRNA NEAT1 could hamper LUAD progression by inhibiting the RhoA/ROCK signaling pathway. These findings provide new insights for LUAD diagnosis and treatment.
Subject(s)
Adenocarcinoma , MicroRNAs , RNA, Long Noncoding , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , Signal Transduction/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Lung , rhoA GTP-Binding Protein/genetics , rhoA GTP-Binding Protein/metabolismABSTRACT
BACKGROUND: Spontaneous preterm birth is challenging to prevent. Only few predictors of spontaneous preterm birth risk have been reported, and further studies on spontaneous preterm birth should be conducted to reduce the number of cases. PURPOSE: The aim of the present study was to explore if anti-ß2-glycoprotein I antibody can be used to predict the risk of spontaneous preterm birth, and its clinical value in assessing the risk of spontaneous preterm birth. METHODS: A total of 302 pregnant women who had delivered between January 2019 and December 2021 were enrolled into the study. The subjects were assigned to the case group (28-33+6 weeks, n = 41; 34-36+6 weeks, n = 96) and control group (37-42 weeks, n = 165) according to the gestational period. The age, body mass index, and gestational days of the two groups were recorded. Blood samples were collected and the levels of anti-ß2-glycoprotein I antibody, white blood cell, red blood cell, hemoglobin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, urea, creatinine, glucose, triglyceride, and total cholesterol were evaluated. Pregnant women diagnosed with sPTB that met the standards after evaluation by the clinician were included in the study. RESULTS: The level of anti-ß2-glycoprotein I antibody was higher in case group than in the control group [(23.93 ± 8.11)Ru/mL vs (11.50 ± 5.33)Ru/mL]. The results showed that anti-ß2-glycoprotein I antibody was an independent risk factor for spontaneous preterm birth. The area under ROC curve of anti-ß2-glycoprotein I antibody to predict spontaneous preterm birth was 0.8875 (95%CI 0.8443-0.9307). The highest predicted value of anti-ß2-glycoprotein I antibody was 16.49Ru/ml. CONCLUSION: Anti-ß2-glycoprotein I antibody has a high clinical significance and can be used by clinicians to evaluate the probability of spontaneous preterm birth.
Subject(s)
Premature Birth , Pregnancy , Humans , Infant, Newborn , Female , Premature Birth/prevention & control , Biomarkers , ROC Curve , Risk Factors , Autoantibodies , GlycoproteinsABSTRACT
PURPOSE: Spontaneous preterm birth (SPB) can't be predicted accurately nowadays. We aim to investigate the value of serum amyloid A(SAA) and interleukin-6(IL-6) for forecasting the risk of SPB. METHODS: A total of 302 pregnant women who completed delivery in our hospital from January 2019 to December 2021 were included. According to gestational days, they were divided into the case group (28-33+6 weeks, 41 cases; 34-36+6 weeks, 96 cases) and the control group (37-42 weeks, 165 cases). The general data of the two groups were analyzed and the values of SAA and IL-6 in speculating the risk of SPB were studied in this study. RESULTS: The levels of SAA and IL-6 in the case group were higher than those in the control group(P < 0.05), and the most practical value of SAA and IL-6 access SPB risk were 17.35 mg/L, 112.41 pg/mL respectively. The area under the ROC curve of diagnosis to predict SPB were 0.8849, 0.8664. CONCLUSIONS: The assessment of SPB risk by SAA and IL-6 bearscertain clinical value, which could assist clinicians in recognizing and evaluating the potential dangers of SPB.
